載入中
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
前收盤價
US$7.39
−US$0.07 · -0.94%
盤後
US$7.3005
−US$0.0895 · -1.21%
10月13日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
日內區間
目前US$7.39
52週區間
目前US$7.39
盤中時間採用ET。市場資料可能有所延遲。
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
日內區間
目前US$7.39
52週區間
目前US$7.39
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3.12億 USD | 4347.22萬 USD | — | 6.54萬 USD | 19.09萬 USD |
| 銷貨成本 | 3596.1萬 USD | 319.05萬 USD | 20.56萬 USD | 3734 USD | 14.89萬 USD |
| 毛利 | 2.76億 USD | 4028.16萬 USD | −20.56萬 USD | 6.17萬 USD | 4.2萬 USD |
| 研究與開發 | 1933.3萬 USD | 394.23萬 USD | 1315.51萬 USD | 1067.95萬 USD | 1313.3萬 USD |
| 銷售、一般及管理費用 | 3016.6萬 USD | 5869.58萬 USD | 3580.27萬 USD | 2000.61萬 USD | 1634.66萬 USD |
| 營業費用 | 1.26億 USD | 6263.8萬 USD | 4875.22萬 USD | 3068.56萬 USD | 2947.96萬 USD |
| 利息收入 | 384.6萬 USD | 257.88萬 USD | 268.19萬 USD | 32.6萬 USD | 1.44萬 USD |
| 利息支出 | 278.2萬 USD | 3.64萬 USD | 3.43萬 USD | 2.65萬 USD | 1.59萬 USD |
| 折舊和攤銷 | 1454.9萬 USD | 31萬 USD | 7.08萬 USD | 8.46萬 USD | 6.19萬 USD |
| 營業利益 | 1.5億 USD | −2235.64萬 USD | −4895.78萬 USD | −3062.4萬 USD | −2943.76萬 USD |
| 淨利 | 1.63億 USD | −1793萬 USD | −4633.92萬 USD | −2970.17萬 USD | −2821.02萬 USD |
公司資料更新於 2026年10月14日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$14.50
上漲空間 96.21%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2019年3月26日 | 1:5 | — | — |
已生效 2019年3月26日
1:5
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1840.1萬0.00%2.3兆 USD0.03%US$381.32-0.07%
Avantis U.S. Small Cap Value ETFAVUV1698.11萬0.05%309.17億 USD0.25%US$120.61+0.56%
iShares Russell 2000 ETFIWM1439.81萬0.02%777.48億 USD0.19%US$276.7-0.43%
Vanguard Extended Market ETFVXF697.56萬0.01%954億 USD0.05%US$232.54-0.42%
State Street SPDR S&P Pharmaceuticals ETFXPH579.53萬1.24%4.61億 USD0.35%US$62.10-2.98%
iShares Russell 2000 Value ETFIWN507.73萬0.04%137.52億 USD0.24%US$210.99-0.05%
Pacer US Small Cap Cash Cows ETFCALF494.58萬0.14%36.29億 USD0.59%US$55.34+1.06%
Vanguard Russell 2000 ETFVTWO353.95萬0.02%180億 USD0.06%US$111.77-0.45%Vanguard Morningstar Total Stock Market ETFVTIAvantis U.S. Small Cap Value ETFAVUViShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Russell 2000 Value ETFIWNPacer US Small Cap Cash Cows ETFCALFVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
